What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?
16 equities research analysts have issued 1-year target prices for bluebird bio's shares. Their predictions range from $37.00 to $135.00. On average, they anticipate bluebird bio's stock price to reach $87.54 in the next twelve months.
When will bluebird bio announce their earnings?
bluebird bio is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.
What are analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (2/9/2017)
Jefferies Group LLC analysts commented, "We seek to update our research as appropriate, but various regulations may prevent us from doing so." (1/10/2017)
Who owns bluebird bio stock?
bluebird bio's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (16.32%), Baillie Gifford & Co. (13.84%), State Street Corp (4.16%), Franklin Resources Inc. (2.48%), Eventide Asset Management LLC (1.58%) and Arrowpoint Asset Management LLC (1.22%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, Mitchell H Finer, Nick Leschly and Philip D Gregory.
Who sold bluebird bio stock? Who is selling bluebird bio stock?
bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Franklin Resources Inc., State Street Corp, Allianz Asset Management AG, Clarius Group LLC, Guggenheim Capital LLC, Van ECK Associates Corp and Century Capital Management LLC. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole and Philip D Gregory.
Who bought bluebird bio stock? Who is buying bluebird bio stock?
bluebird bio's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Alyeska Investment Group L.P., Baillie Gifford & Co., Frontier Capital Management Co. LLC, Deerfield Management Co., ARK Investment Management LLC, Arrowpoint Asset Management LLC and Highland Capital Management LP.
How do I buy bluebird bio stock?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of bluebird bio stock cost?
One share of bluebird bio stock can currently be purchased for approximately $76.25.